Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 3:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ca-125 Clear all
Terminated Phase 1 Interventional

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

NCT03162562
View directory record Official record
Conditions
Cancer of Ovary, Neoplasms, Ovarian, Ovarian Cancer Stage IV, Ovarian Cancer Recurrent, Ovarian Cancer Stage III, Ovary Cancer
Interventions
Oregovomab, Poly ICLC
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 20, 2026, 3:40 PM EDT
Not listed Not applicable Interventional

Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

NCT00039559
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Early detection
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years and older · Female only
Enrollment
2,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 20, 2026, 3:40 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

NCT01685255
View directory record Official record
Conditions
Ovarian Cancer, Genitourinary (GU) Tumors
Interventions
Epacadostat, tamoxifen
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 20, 2026, 3:40 PM EDT
Completed Phase 2 Interventional

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

NCT01616303
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Carboplatin, Paclitaxel, oregovomab
Drug · Biological
Lead sponsor
Quest PharmaTech Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Farmington, Connecticut • South Bend, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 20, 2026, 3:40 PM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

NCT01696994
View directory record Official record
Conditions
Ovarian Carcinoma, Ovarian Germ Cell Tumor
Interventions
Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years · Female only
Enrollment
78,216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 20, 2026, 3:40 PM EDT
Completed Not applicable Interventional

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

NCT01121640
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
CA125 assay on Abbott Architect i1000SR platform, HE4 assay on Architect i1000SR platform, Transvaginal Ultrasound
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
25 Years to 80 Years · Female only
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 20, 2026, 3:40 PM EDT
Completed No phase listed Observational

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

NCT00043472
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 20, 2026, 3:40 PM EDT
Completed Not applicable Interventional

A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

NCT00587093
View directory record Official record
Conditions
Ovarian Cancer
Interventions
CA 125 and CT scan
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
5
States / cities
Baltimore, Maryland • Basking Ridge, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 20, 2026, 3:40 PM EDT
Completed Phase 2 Interventional

Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

NCT00083928
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Carcinoma
Interventions
Å6 subcutaneous injection
Drug
Lead sponsor
Ångstrom Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
24
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 20, 2026, 3:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prophylactic Salpingectomy With Delayed Oophorectomy

NCT01907789
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Ovarian Cancer Screening, Prophylactic Salpingectomy with Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, Questionnaire, Transvaginal Ultrasound, Phone Call
Other · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 47 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2030
U.S. locations
2
States / cities
Evanston, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 20, 2026, 3:40 PM EDT
Terminated Phase 3 Interventional

Clinical Trial for Ovarian Cancer (OvaRex®)

NCT00050375
View directory record Official record
Conditions
Ovarian Cancer
Interventions
oregovomab
Drug
Lead sponsor
Unither Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
62
States / cities
Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Sep 20, 2026, 3:40 PM EDT
Completed No phase listed Observational

Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass

NCT02109367
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
Southern Illinois University
Other
Eligibility
30 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 20, 2026, 3:40 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

NCT06469281
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions
27T51, Cemiplimab, Bevacizumab
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 20, 2026, 3:40 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

NCT01292733
View directory record Official record
Conditions
Ovarian Diseases, Ovarian Neoplasms
Interventions
Laboratory Tumor Marker Analysis, Transvaginal Ultrasound, Health Status Questionnaire
Other
Lead sponsor
Swedish Medical Center
Other
Eligibility
30 Years and older · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 20, 2026, 3:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions
Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 3:40 PM EDT
Terminated Not applicable Interventional

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

NCT02441140
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Culdocentesis, Vaginal Swab, Chromopertubation, Blood collection, Tissue collection
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 20, 2026, 3:40 PM EDT
Recruiting No phase listed Observational

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

NCT05051722
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions
Vaginal Fluid Collection, Blood Collection
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 20, 2026, 3:40 PM EDT